The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer

Ranjeeta Thapa 1,2 and George D. Wilson 1

1 Department of Radiation Oncology, Beaumont Health System, Royal Oak, MI 48073, USA
2 Department of Physics, Oakland University, Rochester, MI 48309, USA

Correspondence should be addressed to Ranjeeta Thapa; rthapa@oakland.edu

Received 26 December 2015; Accepted 27 March 2016

CD44 is a cell surface HA-binding glycoprotein that is overexpressed to some extent by almost all tumors of epithelial origin and plays an important role in tumor initiation and metastasis. CD44 is a compelling marker for cancer stem cells of many solid malignancies. In addition, interaction of HA and CD44 promotes EGFR-mediated pathways, consequently leading to tumor cell growth, tumor cell migration, and chemotherapy resistance in solid cancers. Accumulating evidence indicates that major HA-CD44 signaling pathways involve a specific variant of CD44 isoforms; however, the particular variant almost certainly depends on the type of tumor cell and the stage of the cancer progression. Research to date suggests use of monoclonal antibodies against different CD44 variant isoforms and targeted inhibition of HA/CD44-mediated signaling combined with conventional radio/chemotherapy may be the most favorable therapeutic strategy for future treatments of advanced stage malignancies. Thus, this paper briefly focuses on the association of the major CD44 variant isoforms in cancer progression, the role of HA-CD44 interaction in oncogenic pathways, and strategies to target CD44-overexpressed tumor cells.

1. Background

In cancer biology, cancer cell progression is defined by increased proliferation, invasion, migration, and metastasis of cancerous cells to other parts of the body. Tumor cell heterogeneity plays a major role in cancer progression and metastasis [1]. This heterogeneity was initially attributed to clonal expansion, in which various clones are frequently generated due to the sequential genetic and/or epigenetic alterations in response to certain carcinogens during cancer development, with the daughter cells of more dominant clones overtaking the cells of other malignant clones in a wave-like fashion. However, an alternative view also exists called the cancer stem cell (CSC) hypothesis. According to this hypothesis, heterogeneity and hierarchy among all of the cells exist as a consequence of asymmetric division of cancer stem cells (CSCs) within the tumor mass, and all other cells comprising the tumor bulk are the result of differentiated CSCs [2]. The CSCs have ability to self-renew and form pools of precursors like normal stem cells; however, CSCs demonstrate deregulated self-renewal/differentiation processes and generate daughter cells that are arrested at various stages of differentiation [3].

Many studies support the role of CSCs and their specific markers associated with the malignancies. One of the compelling markers in tumor malignancies is cluster of differentiation 44 (CD44). The CD44 antigen is a single polypeptide chain, single pass, and cell surface glycoprotein encoded by the CD44 gene [4]. CD44 is a large highly conserved and complex gene, which consists of 19 exons located on human chromosome 11 and mouse chromosome 2 [5, 6]. In the human CD44 gene, exons 1–5 and 16–20 produce the standard form of CD44 (CD44s; ~85 kDa). The remaining exons 6–15 are alternatively spliced to form the variant forms of CD44 (CD44v) and referred to as variant exons 1–10 (v1–10) [7, 8] (Figure 1). Ten CD44v exons are detected in the mouse, and nine variant exons are detected in man. Alternative splicing and posttranslation modification are highly regulated in CD44v isoforms and, theoretically, multiple splicing possibilities could give rise to...
many alternative varieties of CD44v isoform. However, very few of them have been verified experimentally [9, 10].

Several experimentally verified CD44v forms have been shown to be directly involved in many malignant tumors and some correlate with metastatic progression [10] (Table 1). CD44v isoforms are differentially expressed in both normal and malignant cells, and the existence of CD44 isoform expression is clearly confirmed by both histological and cellular studies [11]. Table 1 describes the major CD44v associated with cancer progression and metastasis.

Recent evidence has strengthened the potential role of CD44 in CSCs and their influence on disease progression and treatment outcome. In solid cancers CSCs were first defined based on CD44 expression by flow cytometry as CD44bright and CD44dim populations. It has been shown that CD44bright but not CD44dim is capable of regenerating a heterogeneous tumor and demonstrating self-regeneration when transplanted into immune-deficient mice [12]. CD44bright also expresses high levels of the stem cell marker BMI-1 gene, encoding a self-renewal protein found in embryonic stem cells that contains with cytokeratin 5/14, a basal cell marker. This transmembrane protein is commonly associated with many physiological and pathological processes when it is bonded to certain ligands [9].

Although other extracellular matrix components such as osteopontin, collagens, growth factors, and metalloproteinases can bind to CD44, hyaluronan (HA) is the most common and immediate ligand for CD44. All isoforms of the CD44 variants membrane receptor share a common ligand-binding region for HA [11, 13]. HA is produced by hyaluronan synthase, an integral plasma membrane protein, and is released directly into the extracellular matrix. HA is a large, linear, and anionic polysaccharide which is composed of tandem disaccharide repeats of β-1,4-D-glucuronic acid-β-1,3-D-N-acetylglucosamine [14, 15]. As an important component of the extracellular matrix, HA contributes significantly in many cellular processes, for example, cell adhesion, cell migration, innate immunity, wound healing, and cancer progression [16].

An accumulation of evidence indicates that HA-CD44 interaction in the extracellular domain promotes multiple signaling pathways which play a crucial role in tumor cell progression in a variety of solid tumor malignancies (Figure 2). As described in Figure 2, HA is produced and extruded by hyaluronan synthases in the plasma membrane and is directly released into the extracellular matrix. This HA interacts multivalently with CD44 to activate/regulate many signaling domains within the plasma membrane such as receptor tyrosine kinases (ErbB2 and EGFR) and transforming growth factor-β receptor type 1 (TGFβR1) [17]. In addition, the HA-CD44 interaction also mediates nonreceptor kinases (Src family) or Ras family GT-Pases [18]. The HA-CD44 interaction further facilitates the complex formation of several adapter proteins such as Vav2, Grb2, and Gab-1 which

![Figure 1: The plot shows (a) CD44 gene and (b) protein structure. Figure is adapted from Louderbough and Schroeder, 2011 [161].](image)
Figure 2: The influence of tumor cell produced by hyaluronan on cell signaling cascades. Figure is adapted from Toole, 2009 [78].

Table 1: CD44v expression in varieties of tumor types. Table is adapted from Martin et al., 2003 [162].

| Human tumors                          | Change in CD44 expression | Association in tumor progression |
|---------------------------------------|---------------------------|---------------------------------|
| Acute myeloid leukemia                | 2 CD44v6                  | Correlates with poor prognosis   |
| Colorectal carcinoma                  | CD44v3                    | Correlates with poor prognosis   |
| Gastric carcinoma                     | 3 CD44v5, v6, v9          | Upregulated during disease progress [162, 164] |
| HCC                                   | 4 Upregulation of CD44s and v5, v6, v7-8, v10 | Correlates with poor prognosis [38] |
| Non-small cell lung carcinomas        | Upregulation of CD44v6    | Correlates with metastases and poor prognosis [51, 165] |
| Melanoma                              | 5 CD44v3                  | Correlates with metastases [37]  |
| Multiple myeloma                      | CD44v9                    | Upregulated during disease progress [166] |
| Nodular sclerosing Hodgkin’s disease  | 6 CD44v10                 | Upregulated during disease progress [167] |
| 7 Non-Hodgkin’s lymphoma              | 8 CD44v6                  | Correlates with poor prognosis [168, 169] |
| Oesophageal squamous cell carcinoma   | 9 v2                      | Correlates with poor prognosis [170] |
| Oral squamous cell carcinoma          | Downregulation of CD44v4, v5, v9 | Correlates with metastases and poor prognosis [39, 44] |
| Pancreatic adenocarcinoma             | CD44v6                    | Correlates with poor prognosis [67] |
| Primary pancreatic cancer             | CD44v2 and v6             | Correlates with poor prognosis [68] |
| Thyroid carcinoma                     | Downregulation of CD44s   | Correlates with poor prognosis [171] |
| Urothelial carcinoma                  | CD44v6                    | [172, 173]                       |
| Uterine cervical carcinoma            | CD44v6, v7-8              | Correlates with poor prognosis [174, 175] |

mediate the interaction of CD44 with upstream effectors like RhoA, rac1, and Ras [18–20]. These receptors further activate several oncogenic pathways such as the mitogen activated protein kinases (MAPK) and PI3 kinases/akt pathways that consequently promote tumor cell proliferation, survival, migration, invasion, and chemoresistance [18]. In some cases, heparan sulphate chains (carbohydrate side groups on CD44 variant region) associate with regulatory growth factors that activate C-Met receptors which further drive these oncogenic pathways [21]. In addition, HA-CD44 interaction also stimulates multidrug and metabolic transporters that are strongly associated with therapy resistance [17, 19, 22]. Finally, HA-CD44 interaction induces cytoskeletal changes that promote tumor cell motility and invasion [21, 23, 24]. The bulk of the current evidence suggests that different CD44 variants are associated with these interactions [11, 25–31].
2. Different CD44v Association with Cancer Progression

A single CD44 polypeptide is divided into three major domains: extracellular binding domain, transmembrane domain, and cytoplasmic domain. Further, all CD44v isoforms contain a conserved extracellular binding domain for HA and a common cytoplasmic domain for triggering cell signaling pathways. The coupling of HA with the CD44 extracellular domain correlates with a multiple signaling kinases transduction in the cytoplasmic domain, which determines how one family of molecules regulates several cellular processes. CD44v isoforms are expressed in both normal and tumor cells at different levels, indicating that the CD44 isoforms are also an essential component for normal cellular functions [32]. As mentioned earlier, exon splicing mechanisms can lead to the overexpression of CD44v isoforms in cancer cells; their role and the degree of expression vary in different malignancies. In certain cancers, CD44v isoforms are considered to be tumor progression promoters [33–38], while in other cancers, they may be involved as tumor suppressors [26, 39–44].

There are many possible factors for these varying results. For example, different research groups use different methods for detecting CD44 such as immunohistochemistry or PCR with different antibodies which makes it difficult to compare the results since some CD44v epitopes may not be targeted by some of the antibodies due to the posttranslational modification, resulting in conformational changes of the protein. In addition, tumor heterogeneity may also play a major role in these discrepant results [45]. This section only focuses on the role of CD44v as tumor promoters in some major cancers.

2.1. Colorectal Cancer. In colon cancer, CD44v3 has been shown to activate invasion and resistance to apoptosis, and CD44v6 has been associated with tumor metastasis and decreased disease-free survival [30, 46]. Yamaguchi et al. [47] showed that CD44v8–10 isoforms play a role in metastasis of colorectal cancer and are useful independent factors for the prediction of prognosis in colorectal cancer patients.

Further, Du et al. [25] demonstrated that a single CD44 bright cell from a tumor could form a sphere in vitro which had characteristic stem cell properties and was able to generate a xenograft tumor resembling the properties of the primary tumor. Also, knockdown of CD44 strongly prevented clonal formation and inhibited tumorigenicity in a xenograft model, concluding that CD44 had a potential to be a CSC marker for colorectal cancer (CRC). In addition, Ozawa et al. [48] evaluated primary CRC cell isolates to determine the significance of several CSC markers, including CD44, as predictors of tumorigenesis and prognosis. CD44-positive cells from fresh clinical samples of CRC were differentiated by flow cytometric sorting and evaluated for tumorigenicity following subcutaneous transplantation into NOD/SCID mice. Cancer stem cell marker expression was tested in both xenografts and a complementary DNA library compiled from CRC patient samples. They demonstrated that CD44 bright populations were significantly more tumorigenic than the total cell population. The clinical samples expressed several CD44 variants with CD44v2 being specifically over-expressed in both primary tumors and xenografts in comparison with the normal mucosa. A prognostic assay using qRT-PCR showed that the CD44v2 bright group had a significantly worse prognosis compared to the CD44v2 dim group, concluding the prognostic significance of CD44v2 upregulation in CRC. Recently Todaro et al. [49] showed that colorectal cancer stem cells (CR-CSCs) express CD44v6, which is both a functional biomarker and therapeutic target and is essential for their migration and generation of metastatic tumors.

2.2. Lung Cancer. In a study with squamous cell carcinoma and bronchioalveolar carcinoma of lung malignancies, CD44v5 and CD44v6 have been shown to promote tumor metastasis [29, 50]. Miyoshi et al. [51] showed that CD44v3, CD44v5, CD44v6, or CD44v7 was expressed in 28 of 31 (90.3%) non-small cell lung carcinomas (NSCLCs) tissue samples using RT-PCR, and the expression of the CD44v6 was associated with lymph node metastasis. Recently, it has been shown that CD44v6 expression in NSCLC is associated with squamous subtype, lymph node metastasis, and a poor survival and should be considered as a new important prognostic marker [52–54].

Further, Leung et al. [55] investigated whether the stem cell hypothesis was applicable to lung cancers by using ten lung cancer cell lines (H1650, HKULC2, H1299, HKULC4, HCC827, H23, HCC1833, A549, H441, and H1648). They screened the expression profile of CD44 along with two other putative surface markers CD34 and CD133 and nuclear markers BMII and OCT4 by flow cytometry. There was variation in the expression level of all the surface markers tested, and CD44 was the major marker expressed by H1299 and H23 cells. Both the nuclear markers, BMII and OCT4, were expressed in the majority of cancer cells in all cell lines studied. Further, CD44 bright cells of four cell lines showed spheroid body formation and in vivo tumor initiation ability. When CD44 bright cells of H1299 cell line were used for the testing of in vivo tumor transplantability, the primary xenografts consisted of mixed CD44 bright and CD44 low cells in similar ratios as the parental H1299 cell line, supporting in vivo differentiation. Using RT-PCR study, they showed that both freshly sorted CD44 bright and CD44 low cells derived from CD44 bright-initiated tumors expressed the pluripotency genes OCT4/POUS51, NANOG, and SOX2 (stemness markers); however CD44 low did not. Further, CD44 bright cells were more cisplatin resistant than CD44 low cells, concluding that stem cell-like properties are enriched in CD44 expressing subpopulations of some lung cancer cell lines.

2.3. Breast Cancer. In breast cancer, CD44v3, CD44v5, and CD44v6 have been associated with metastasis [27]. Tempfer et al. [56] investigated the expression of CD44 isoforms CD44v5, CD44v6, and CD44v7–8 in 115 human breast cancer specimens by means of immunohistochemistry and found that these variants are strongly associated with axillary lymph node metastasis. Ryś et al. [57] estimated the frequency of CD44 expression as well as two CD44 isoforms CD44v3 and
CD44v5 in female breast cancer, concluding that CD44v3 significantly correlated with the presence of metastases to the lymph nodes.

Further, CD44bright/CD44− cells either singly or in combination with other stem cell markers have shown tumorigenic potential [28]. In a study with breast cancer cells (MDA-MB-231, MDA-MB-436, Hs578T, SUM1315, and HBL-100 cell lines) having CD44+/CD24− subpopulation showed higher levels of expression of proinvasive genes and had highly invasive properties [58]. Al-Hajj et al. [59] initially identified and isolated the tumorigenic cells as CD44+CD24low lineage− in breast cancer tissues from eight of nine patients. As few as 100 cells with this phenotype were able to form tumors in mice, while tens of thousands of cells with alternate phenotypes were unable to form tumors. The tumorigenic subpopulation could be serially passaged, and the tumor formed in each time of passage contained mixed population of additional CD44+/CD24low lineage− tumorigenic cells as well as the phenotypically diverse mixed populations of nontumorigenic cells present in the original tumor.

Further, Olsson et al. [60] demonstrated that CD44 variants were heterogeneously expressed in breast cancer and correlated with tumor subtypes and cancer stem cell markers. They showed that a high expression of CD44v2–10 isoform, which retain all variant exons, was correlated to positive steroid receptor status, low proliferation, and luminal A subtype. The CD44v3–10 showed similar correlation, while high expression of CD44v8–10 was correlated to positive EGFR, negative/low HER2 status, and basal-like subtype. The CD44v3–10 showed similar correlation, while high expression of CD44v8–10 was correlated to positive EGFR, negative/low HER2 status, and basal-like subtype. Further, the CD44 variants described above were associated with all tumors that were characterized as positive for CD44+/CD24− phenotype by immunohistochemistry. These findings suggested the involvement of CD44 variants in specific oncogenic signaling pathways.

2.4. Leukemia. In leukemia, several CD44 variants are overexpressed in malignant hematopoietic cells and strongly involved in metastasis and shorter survival rates [31]. For example, bone marrow progenitors express CD44v3, CD44v6, CD44v9, and CD44v10, while lymphocytes and monocytes express CD44v3, CD44v6, and CD44v9 following stimulation with inflammatory cytokines [61]. CD44 variant expression has been associated with poor prognosis and increased metastatic spread in a number of hematological and nonhematological malignancies. Overexpression of CD44v6, CD44v9, and CD44v10 has been associated with poor prognosis in non-Hodgkin's lymphoma and myeloma and CD44v6 with poor prognosis and shorter survival rate in acute myeloid leukemia (AML) [31]. In acute lymphoblastic leukemia (ALL), CD44v6 was shown to be expressed on bone marrow cells from patients with poor risk ALL, but not on those from patients with a good prognosis [62, 63].

Permanent cure of leukemia requires elimination of leukemic stem cells (LSCs), the only cell type capable of initiating and maintaining the leukemic clonal hierarchy. For example, targeting of the stem cell marker CD44, highly expressed in AML cells, resulted in eradication of leukemic stem cells (LSCs) [64].

Though blockade of CD44 is considered a therapeutic option for the elimination of LSCs, anti-panCD44 can interfere with hematopoiesis. Thus, targeting CD44 variant isoforms in leukemic malignancies can inhibit leukemic growth without attacking hematopoiesis. For example, recently, Erb et al. [65] showed that CD44s and CD44v10 expression distinctly influenced niche embedding of hematopoietic stem cells and targeting CD44v10 with anti-CD44v10 prolonged the survival time.

2.5. Pancreatic Cancer. In pancreatic cancer, different CD44v isoforms are associated with malignancies. Metastasis-specific isoforms of CD44 were first documented in a model of rat pancreatic adenocarcinoma (CD44v4–7 and CD44v6–7) and subsequently in other cancers [41]. Rall and Rustgi [41] also investigated that CD44v6 isoform or CD44v8–10 are expressed in primary and metastatic human pancreatic adenocarcinoma, which is usually metastatic at the time of diagnosis and has the worst prognosis of all gastrointestinal cancers [41, 66]. They used radiolabeled RT-PCR/PAGE and Southern blot hybridization to analyze clinical specimens of primary and metastatic pancreatic cancer for the expression of CD44s, CD44v8–10, and CD44v6 isoforms. There was no difference in the expression of CD44s and CD44v8–10 among the primary and metastatic adenocarcinomas and the control specimens of pancreata. However, CD44v6 was found in metastatic lesions. Later, Gansauge et al. [67] showed that CD44v6 were expressed on both adenocarcinoma and normal pancreatic cells, while CD44v5 were strongly expressed on adenocarcinomas. Gotoda et al. [68] further tested whether CD44v6 is a useful marker for evaluating the prognosis of pancreatic cancer patients. They also attempted to assess the clinicopathological implications of the CD44v2 for pancreatic cancer. Their results showed that both CD44v6 and CD44v2 were expressed on tumor cells, and their expression was correlated with decreased overall survival.

Recently, Li et al. [36] studied the expression pattern of CD44v2–CD44v10 and CD44s and found that high expression of CD44v6 and CD44v9 and low expression of CD44s (CD44v6+, CD44v9+, and CD44s−) were associated with pancreatic carcinoma metastasis and progression and that CD44v6+/CD44s− was an independent risk factor affecting overall survival.

Further, Kiuchi et al. [69] demonstrated that pancreatic cancer cells (PCCs) with an epithelial phenotype upregulate cell surface expression of CD44v9, an important CSC marker, during the mitotic phases of the cell cycle. They found PCCs with an epithelial phenotype upregulated cell surface expression of CD44v9 in prophase, metaphase, anaphase, and telophase and downregulated CD44v9 expression in late-telophase, cytokinesis, and interphase. In addition, flow-sorted CD44v9-negative PCI-55 cells resumed CD44v9 expression when they reentered the mitotic stage and CD44v9 (bright) mitotic cells showed intracellular expression of the multidrug resistance protein 1 (MDRI).

2.6. Head and Neck Cancer. In head and neck cancer, Reategui et al. [70] first characterized the expression of
CD44v3-containing isoforms. Both cell culture and histological studies were performed using HNSCCs cell lines and tissues. The tissue study identified that high levels of CD44v3 were expressed in tumor tissues compared to normal tissue [70]. The cellular study showed that an increased level of CD44v3 did not affect the rate of proliferation; however, a significant increase in migration was observed [70]. Wang et al. [12, 13] reported studies utilizing HNSCC cell lines and clinical tissue specimens and found that CD44v3, CD44v6, and CD44v10 isoforms were associated with HNSCC lymph node metastasis and advanced T status, perineural invasion and decreased survival, and distant metastasis and radiation failure, respectively. Kawano et al. [71] used immunohistochemical analysis using monoclonal antibody against CD44v6 isoforms in paraffin-embedded mesopharyngeal cancer tissues and found that CD44v6 expression correlated with tumor invasion, lymph node metastasis, and shorter survival.

Recently CD44v9 has emerged as a novel marker of cancer stemness in a variety of solid tumors including HNSCC [72–77]. The CD44v9 is active though increasing the intracellular levels of glutathione (GSH) when combined with the functional subunit of the cystine/glutamate transporter (xCT), resulting in cellular protection from reactive oxygen species (ROS) and oxidative stress, which is one of the distinct characteristics of CSCs [72, 73].

Aso et al. [73] evaluated the expression levels of CD44v9 protein in clinical samples (biospy and surgically removed tumor specimens) of 102 patients following induction concurrent chemoradiotherapy (CCRT). They found that CD44v9 expression level in biopsy specimens did not correlate with the patients having favorable response to CCRT or their survival. However, in nonresponding patients, the CD44v9-positive group showed significantly worse prognosis compared to the CD44v9-negative group. Based on tumor (T), node (N), response to CCRT, and CD44v9 positivity analyses, the CD44v9 positivity was significantly correlated with poor prognosis, along with advanced N stage. Further, the survival rate of the CD44v9-induced group was significantly worse compared to the CD44v9-noninduced group. These results concluded that CCRT-induced CD44v9-expressing CSCs appear to be a major hurdle to CCRT.

3. Use of Anti-CD44 Monoclonal Antibodies to Target CD44

Targeting CD44 using monoclonal antibody-mediated pathways is a novel targeted therapy in cancer treatment. Anti CD44 antibodies developed against various highly expressed CD44 variants have the potential to inhibit and disrupt CD44-matrix interactions. There are two basic strategies in which either the native antibody is employed to bind and neutralize the receptor by competitive inhibition of its ligand consequently preventing the receptor-signaling cascade or radioisotopes, toxins, or chemotherapeutic agents can be attached to the antibodies to cause cancer cell death. More recently, the use of antibody-attached nanoparticle systems is receiving increasing attention.

A study with human acute myeloid leukemia (AML) cell showed that an activated anti-CD44 antibody (H90) reduced the leukemic repopulation by alteration of the behavior of AML leucocyte stem cells (LSC) by annulling AML LSC homing, resulting in tumor-initiating cell death [64]. Greater survival rates were also observed in mice xenografts of BCR-ABL-expressing leukemic cells after blockade of CD44 by anti-CD44 antibodies [78, 79]. Verel and colleagues developed a chimeric (BIWA-2) and two humanized (BIWA-4 and BIWA-8) monoclonal antibodies against CD44v6 which were derivatives of the BIWA-1 monoclonal antibody [80] to target CD44v6 in head and neck cancer xenografts. In comparison with the murine monoclonal antibody, U36, and BIWA-1, they showed that the MABs bound to CD44v6 with an up to 46-fold difference in affinity ranking: U36 < BIWA-4 < BIWA-8 < BIWA-1 ~ BIWA-2. In terms of biodistribution in vivo, significant differences were observed between the pairs: U36 versus BIWA-1 (35.0-fold difference), BIWA-4 versus BIWA-2 (14.0-fold), and BIWA-4 versus BIWA-8 (4.0-fold). When the antibodies were assessed and radioimmunotherapeutics (RIT) labeled with 186Re, the lower-affinity monoclonal antibodies (such as U36 and BIWA-4) showed a higher degree and specificity of tumor localization. In other studies, BIWA-4 was radiolabeled with Tc-99 and Re-186 and conjugated with a cytotoxic drug, mertansine, and tested for its efficacy in targeting CD44v6 antigen [81, 82]. These studies verified that radiolabeled BIWA-4 can be administered safely and showed some promising results in clinical trials with HNSCC patients without any human anti-human antibody (HAHA) responses. However, a phase I dose escalation study with HNSCC patients exhibited dose limiting skin toxicity in nontumor surrounding tissue likely due to CD44v6 expression in normal keratinocytes [83]. The majority of skin toxicity was reversible; however, the incident led to the discontinuation of the study with the conclusion that this antibody was not suitable for human studies. A similar study in the following year was performed to target CD44v6 with the prodrug bivatuzumb mertansine (BIWI 1) and deconjugated BIWI 1 in a dose escalation phase I clinical trial with 31 HNSCC patients [84]. The purpose of this study was to characterize the pharmacokinetics and immunogenicity and safety of these immunoconjugates. Both agents were administered safely and found to be appropriate as novel conjugates with the maximum tolerated dose (300 mg/m2) of this novel approach. These studies suggest CD44, particularly CD44v6 isoform, remains an attractive target for cancer treatments.

In alternative approaches nanoprobes, such as the combination of nanorods and tumor sensitizing drugs, have been investigated [85]. Anti-CD44 antibodies-conjugated gold nanorods have been used to sensitize MCF-7 breast cancer that overexpresses the CD44 surface marker [85]. The absorption of near infrared light by the gold nanorod led to a local rise in the temperature; as a result, photoablation of the CD44bright cells occurred.

4. Use of HA Oligomers

The disruption of HA-CD44 interaction by using HA oligomers is another approach to target CD44. This approach
comprises replacing the multivalent interaction of high molecular weight (HMW) HA and CD44 with monovalent interaction of small oligomers of HA (6–18 saccharide units of HA).

HA is a widely known HMW glycosaminoglycan polymer from which oligosaccharides of desired size can be readily obtained [86]. HA is produced by cell membrane-bound protein called hyaluronan synthase (HAS) [87]. There are three types of HASs involved in HA biosynthesis: HAS-1, HAS-2, and HAS-3 [88]. HAS-1 is encoded by the gene has1 linked on 19q13.3 human chromosome. HAS-2 is encoded by the has2 gene localized at chromosome 8q24.12. It is responsible for generation of HA in response to shock, inflammation, and tissue repair. HAS-3 is encoded by has3 gene localized on chromosome 16q22.1 [87, 89]. HAS-1 and HAS-3 generate HA with broad size distributions (200,000 to two million Daltons), whereas HAS-3 generates HA with extremely large sizes (>two million Daltons) [90–92].

Small oligomers of HA suppress antiapoptotic signaling pathways in cancer cells and inhibit the activity of transporters that enhance the multidrug resistances to some chemotherapeutic agents [17, 93]. Initial studies showed that HA oligomers of 3–9 disaccharides bind CD44 monovalently and displace stromal HA polymer bound to membrane receptor [94, 95]. Recently these oligomers have also been shown to inhibit HA synthesis [96]. HA oligomer treated tumor cells show disassembly of CD44-transporter and receptor tyrosine kinase (TRK) complexes, internalization of these disassembled components, and weakening of their function [96, 97]. In vivo treatments which inject small HA oligomers, but not the large polymers, induce tumor regression in many human xenograft experiments with various cancer types such as melanoma, carcinoma, glioma, osteosarcoma, and malignant peripheral nerve sheath tumors [98]. Ween et al. [99] reported that small HA oligomers (6–10 disaccharides) were able to block cancer cell adhesion, motility, and invasion in both presence and absence of exogenous HA. In this study, they used three different ovarian cancer cells (OVCA-3, OVCA-5, and SKOV-3) and artificially induced tumor cell motility, invasion, and metastasis in these cells by adding versican and/or exogenous HA, and then, they were treated with HA oligomers. They concluded that HA oligomers are promising inhibitors of ovarian cancer dissemination. In another study, Zeng et al. [86] showed that injecting HA oligomer can potentially inhibit in vivo tumor formation using B16F10 melanoma cell lines. Urakawa et al. [100] studied the effective size of the HA-oligosaccharides required to inhibit the cell growth in highly invasive breast cancer cell line, MDA-MB-231 by testing the effects of HA tetrasaccharides, HA decasaccharides, and high molecular weight HA. The results showed that HA decasaccharides significantly inhibited cell growth, motility, and invasion, whereas HA tetrasaccharides could not. Further, HA disaccharides inhibited the expansion of osteolytic lesions in a mouse bone metastasis model of breast cancer. From this study, they concluded that “HA-oligosaccharides suppressed progression of bone metastasis in breast cancer via interruption of endogenous HA-CD44 interaction and, as such, could be a novel therapeutic candidate to limit bone metastasis of breast cancer.” Moreover, small HA oligomers have shown their potential during in vivo treatments by suppressing tumor growth and/or inducing tumor regression in experiments using xenografts of several tumor types [17, 86, 96, 98, 101, 102].

5. Use of Hayaluronidases

HA can be catabolized by enzymatic and nonenzymatic processes. In the enzymatic process, hyaluronidases (HAases or HYALs) are a class of enzymes that predominantly degrade HA, though they have limited ability to degrade chondroitin and chondroitin sulphates [78, 103]. Human HYALs are encoded by six genes: hyal1, hyal2, and hyal3 localized at 3p21.3 human chromosome and hyal4, ph-20 (or spam1), and pseudogene phyall (that lost its protein-coding ability) localized at chromosome 7q31.3 [88]. Regarding the role of HYALs in cancer, a considerable body of data exist supporting HYALs overexpression and elevated activity in many cancers [104, 105]. Clinical data demonstrate that both hyal1 and hyal2 genes are overexpressed in advanced stages of colorectal disease [104]. In vitro knockdown of hyal1 gene expression in breast cancer cells (MCF7 and ZR-75-30 cells) showed reduced cell growth, adhesion, invasion, and angiogenesis, while induced overexpression of the isoenzyme elevated cell malignancy. Further, in vivo study using MCF7-cells demonstrated that induced hyal1 overexpression in a nude mouse model resulted in increased tumor growth and promoted angiogenesis [105]. A variety of hyal1-expressing tumors such as bladder and prostate, genitourinary tract, head and neck, and brain show a significant amount of expansion in micro vessel density and larger capillaries compared to the non-hyal1-expressing tumors [106–109]. Due to their overexpression in some types of malignancies, HYALs have been considered as a diagnostic marker of the disease [110, 111].

Despite the fact that constitutive HYALs may promote prooncogenic activity of HA, overexpression or exogenous administration of excess amounts of HYALs inhibits tumor potential [103, 106, 107]. Experimental and clinical results of HYALs showed that they can be used as an adjunct to chemotherapy by improving the access of the drugs to the cancer cells which is attributed to their properties of accelerating the transport of numerous endogenous and exogenous substances within the tissue by loosening the cell-cell contact and the intercellular connective matrix [106, 112]. Shuster et al. [113] demonstrated that the tumor volumes in human breast cancer xenografts were significantly decreased by up to 50% upon the intravenous administration of an extremely high dose of HYALs. HYALs have shown their potential to sensitize mouse mammary carcinoma cells (EMT-6 cells) which are sensitive to their antiadhesive effects [78, 114]. Generally HYALs are active by reducing drug diffusion barriers; however, they may also work through degrading high molecular weight HA into the low molecular weight HA [17].

These opposing data described above suggest that HYALs may act as both a tumor promoter and tumor suppressor [78, 106]. To resolve this paradox about their role in cancer,
further investigations have been performed [78, 106]. For example, it has been shown that HYAL-1 acts as a tumor promoter at a naturally expressed level by tumor cells, while above the naturally expressed level (exceeding 100 mU/10⁶ cells) it acts as tumor suppressor through inducing apoptosis [78, 106]. Thus, the function of HYALs (which are not tumor cell-derived), as tumor promoter/suppressor, is a dose-dependent process; however, the tumor cell-derived HYALs function mainly as tumor promoter [106].

6. Use of HA-Mediated Nanoparticle Systems

CD44 can exist in three different forms: low affinity form, high affinity form induced by inflammation, and constitutive high affinity form. On normal cells CD44 is mostly expressed in low affinity form showing less interactions with HA [115], while cancer cells express constitutive high affinity form of CD44 [116]. This provides rationale to utilize HA-conjugated nanoparticles to target CD44-overexpressed cancer cells [14, 15, 117–119].

The main drawbacks of traditional chemotherapy are severe off-target side effects and unwanted toxicity due to the systemic distribution of the chemotherapeutic drugs [120]. Another major challenge is the development of multidrug resistance (MDR) by the tumor cells, which ultimately makes chemotherapy less effective [121–123]. To overcome these limitations, investigators have developed carrier systems that can selectively deliver cytotoxic doses of drugs to cancer cells avoiding the surrounding normal tissue [124–126].

Recently the use of nanoparticle systems for both diagnostic imaging and drug delivery has attracted increasing attention [127]. Their nanometric dimensions and large surface to volume ratio render them suitable for attaching multiple copies of a variety of ligands. In addition, nanoparticles’ unique magnetic, optic, or fluorescent properties make them suitable for biological imaging [128–131]. The nanoparticles used in the biomedical applications include liposomes, polymeric micelles, block ionomer complexes, dendrimers, inorganic and polymeric nanoparticles, nanorods, and quantum dots. All have been tested preclinically or clinically for targeted drug and gene delivery and as agents to enhance dark contrast in magnetic resonance imaging (MRI) [132–134].

Although nanoparticles can be nonspecifically taken up by macrophages, their surface modification with specific ligands to actively target tumor cell specific receptors can potentially enhance the efficiency and selectivity of the delivery [128, 135]. Several studies have indicated that conjugation of HA to a nanocarrier coupled to anticancer drugs such as epirubicin [124], doxorubicin (DOX) [125], paclitaxel (PTX) [126], and mitomycin C (MMC) [124], as well as siRNA, can deliver these agents to CD44-overexpressing cells [136, 137]. The nanoparticles used in these studies have been diverse and include quantum dots [138], carbon nanotubes [139] and nanodots [137, 140], graphene [141], gold nanoparticles [142], iron oxide nanoparticles [143], and silica nanoparticles. For example, Cho et al. [144] used hyaluronic acid-ceramide- (HA-CE-) based self-assembled nanoparticles for the selective delivery of docetaxel (DET) to the CD44-overexpressing cell line (MCF-7) and concluded that the HA-CE-based nanoparticles might be a good anticancer drug delivery system through passive and active tumor targeting. Eliaz and Szoka [125] demonstrated that doxorubicin (DOX) encapsulated in HA-conjugated liposomes was significantly more potent to CD44-overexpressing cells (B16F10, murine melanoma cell line) compared with free DOX and significantly less toxic than the free DOX to CD44-low expressing cells (CV-1, African green monkey kidney cells). They concluded that liposome encapsulated DOX might be a useful targeted drug carrier for the treatment of CD44-overexpressing cells. Most recently, Shen et al. [145] tested coating solid lipid nanoparticles with hyaluronan (HA-SLNs) for targeted delivery of paclitaxel (PTX) to CD44-overexpressing B16F10 melanoma cells. In the in vitro results showed that PTX-loaded HA-SLNs led to efficient intracellular delivery of PTX and induced a significant amount of apoptosis in CD44bright cells. During in vivo experiments with the B16F10-CD44bright lung metastasis model, PTX-loaded HA-SLNs targeted the tumor-bearing lung tissue well resulting in significant antitumor effects with a comparatively low dose of PTX.

In recent years, HA-mediated iron oxide nanoparticles have also been used for targeted delivery [14, 128, 146–148]. For example, Kumar et al. [143] developed HA-iron oxide (HA-Fe₂O₃) nanoparticles and tested their ability to deliver peptides to HEK293 and A549 cells, concluding that HA- Fe₂O₃ nanoparticles can be effective tissue and cell targeting systems. More specifically, the use of magnetic nanoparticles such as superparamagnetic iron oxide nanoparticles (SPIONs) functionalized with HA has been investigated for targeting CD44-overexpressed tumor malignancies and inflammations. SPIONs are inorganic particles having an iron oxide core coated by inorganic materials such as silica and gold and organic materials such as phospholipids, fatty acids, polysaccharides, peptides, or other surfactants and polymers [149–151].

In contrast with the nanoparticles previously discussed, SPIONs’ inducible magnetic properties facilitate them to be aligned in a defined location in the presence of an externally applied alternating current (AC) magnetic field. This property of inducible magnetism of SPIONs renders them suitable for many biological applications in tumor biology, ranging from diagnostics (MRI) to therapeutics (magnetic hyperthermia), and magnetically assisted transfection of cells [151–154].

In terms of using SPIONs as targeting agent for CD44-overexpressed cells, several investigators used HA-conjugated SPIONs [128, 146–148]. Kamat et al. [128] designed and synthesized dextran coated SPIONs conjugated with HA (HA-DESPIONs) on the surface to target activated CD44-overexpressed macrophages which play a crucial role in atherosclerotic plaque development. They characterized HA-DESPIONs by transmission electron microscopy, thermogravimetric analysis, elemental analysis, dynamic light scattering, and high-resolution magic angle spinning NMR and also verified their biocompatibility and colloidal stability in the presence of serum. They concluded that these nanoparticles can potentially become a useful carrier system for
molecular imaging and targeted drug delivery to activated macrophages. El-Dakdouki et al. [146] further elaborated that magnetic nanoparticles conjugated with HA enabled the imaging of atherosclerotic plaques in vivo by MRI. They concluded that the very low dose of nanoparticles with high biocompatibility was able to image atherosclerotic plaques without much delay, establishing these nanoparticles as contrast agents for plaque imaging. The same group of the investigators developed DOX loaded HA-coated nanoparticles (DOX-HA-SPIONs) for imaging and drug delivery to cancer cells [14]. Their studies demonstrated that DOX-HA-SPIONs were much more effective than free DOX in damaging not only drug-sensitive but also multidrug-resistant cancer cells which was attributed to the differential uptake mechanisms and cellular distributions of free DOX and DOX-HA-SPIONs in cancer cells.

In addition to using HA-SPIONs as contrast enhancing agents and drug delivery systems, there are several other therapeutic aspects that can be tested using these nanoparticles. Our group has recently tested the cytotoxicity, radiosensitivity, and hyperthermia sensitivity of HA-DESPIONs in CD44 expressing HNSCC cell lines at clinically relevant radiation dose and temperatures, respectively [155]. Our results demonstrated that HA-DESPIONs are nontoxic and although they do not enhance radiation sensitivity, they did increase the effect of local hyperthermia. These results supported further development of drug-attached HA-DESPIONs in combination with radiation for targeting cancer stem cells and the development of an alternating magnetic field approach to activate the HA-DESPIONs attached to cancer stem cells.

The latter is an emerging strategy for treating cancers through ablative thermotherapy which may offer patients an alternative and minimally invasive treatment option [156, 157]. Magnetic iron oxide nanoparticle induced hyperthermia is being investigated for the treatment of different cancers using both in vitro and in vivo mouse xenograft models [156, 158]. Zhao et al. [156] demonstrated that magnetic nanoparticle-based hyperthermia can be achieved by applying an alternating magnetic field. Using a mouse xenograft model of human head and neck cancer (Tu212 cell line), they showed that the central tumor temperature was dramatically elevated from room temperature to about 40°C within the first 5–10 minutes which resulted in hyperthermia-mediated cell death due to oncoctic necrosis. Huang and Hainfeld [159] reported that magnetic nanoparticles, with a well-tolerated intravenous dose in the presence of applied field of 38 kA/m at 980 kHz, were able to heat tumors to about 60°C in 2 minutes, while avoiding normal surrounding tissues. Most recently, Thomas et al. [160] developed HA-coated PEGylated SPIONs (HA-PEG-SPIONs) and HA-SPIONs and performed hyperthermia studies using SCC7 cell line (squamous cell carcinoma of head and neck). The in vitro results showed 40% reduction in cell viability for both HA-SPIONs and HA-PEG-SPIONs in AMF treated cells. Our preliminary studies using HA-DESPIONs bound to CD44-overexpressing cells in an AMF showed promising data where significant apoptotic cell death was induced in the CD44bright population.

7. Conclusion

Despite the recent success of monoclonal antibodies mediated targeting pathways of CD44 variants and improvement in nanoparticle systems for imaging and treatments, there are several unsolved mysteries and lack of knowledge regarding their clinical application in human trials. This paper reviewed the recent scientific literature regarding the role of HA-CD44 signaling pathways, association of different CD44 variants in varieties of tumor types, and four major ways of targeting CD44 receptors for the treatment. The bulk of the evidence indicates that HA-CD44 interaction plays a crucial role in tumor progression and understanding HA-CD44 regulated signaling pathways may lead to early detection and improvement in the treatments. Research suggests targeted elimination of CD44 variant isoforms by the use of monoclonal antibodies against these variants in combination with standard radio/chemotherapy agents may be a promising future treatment for deadly locoregionally advanced malignancies.

Competing Interests

The authors declare that they have no competing interests.

References

[1] M. Bryne, M. Boysen, C. G. Alfsen et al., “The invasive front of carcinomas. The most important area for tumour prognosis?” Anticancer Research, vol. 18, no. 6, pp. 4757–4764, 1998.
[2] D. G. Tang, “Understanding cancer stem cell heterogeneity and plasticity,” Cell Research, vol. 22, no. 3, pp. 457–472, 2012.
[3] T. Rey a, S. J. Morrison, M. E. Clarke, and I. L. Weissman, “Stem cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859, pp. 105–113, 2001.
[4] R. H. Tammi, A. Kultti, V.-M. Kosma, R. Pirinen, P. Auvinen, and M. I. Tammi, “Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan,” Seminars in Cancer Biology, vol. 18, no. 4, pp. 288–295, 2008.
[5] A. Colombatti, E. N. Hughes, B. A. Taylor, and J. T. August, “Gene for a major cell surface glycoprotein of mouse macrophages and other phagocytic cells is on chromosome 2,” Proceedings of the National Academy of Sciences of the United States of America-Biological Sciences, vol. 79, no. 6, pp. 1926–1929, 1982.
[6] P. N. Goodfellow, G. Banting, M. V. Wiles et al., “The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody Fl0.44.2, is on human chromosome 11,” European Journal of Immunology, vol. 12, no. 8, pp. 659–663, 1982.
[7] G. R. Screaton, M. V. Bell, D. G. Jackson, F. B. Cornelis, U. Gerth, and J. I. Bell, “Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 24, pp. 12160–12164, 1992.
[8] G. R. Screaton, M. V. Bell, J. I. Bell, and D. G. Jackson, “The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1
(CD44) homing receptor: comparison of all 10 variable exons between mouse, human, and rat," The Journal of Biological Chemistry, vol. 268, no. 17, pp. 12235–12238, 1993.

[9] A. Raja-Raj, A. Stokes, B. K. Bloor et al., "CD44 expression in oro-pharyngeal carcinoma tissues and cell lines," PLoS ONE, vol. 7, no. 1, Article ID e28776, 2012.

[10] S. J. Wang, G. Wong, A.-M. de Heer, W. Xia, and L. Y. W. Bourguignon, "CD44 Variant isoforms in head and neck squamous cell carcinoma progression," Laryngoscope, vol. 119, no. 8, pp. 1518–1530, 2009.

[11] S. J. Wang, G. Wong, A.-M. De Heer, W. Xia, and L. Y. W. Bourguignon, "CD44 Variant isoforms in head and neck squamous cell carcinoma progression," Laryngoscope, vol. 119, no. 8, pp. 1518–1530, 2009.

[12] E. Gilad, "CD44 interaction with Na^+ and function of hyaluronan: an overview," International Journal of Drug Delivery, vol. 11, no. 3, pp. 110–121, 2008.

[13] L. V. W. Bourguignon, "Hyaluronan-mediated internalization of RhoGTPase signaling and cytoskeleton function promotes tumor progression," Seminars in Cancer Biology, vol. 18, no. 4, pp. 251–259, 2008.

[14] L. V. W. Bourguignon, P. A. Singleton, F. Diedrich, R. Stern, and E. Gilad, "CD44 interaction with Na^+ and function of hyaluronan in mouse and human cell lines," The Journal of Biological Chemistry, vol. 279, no. 26, pp. 26991–27007, 2004.

[15] L. V. W. Bourguignon, P. A. Singleton, F. Diedrich, "Hyaluronan-CD44 interaction with Rac1-dependent protein kinase N-γ promotes phospholipase Cγ1 activation, Ca^{2+} signaling, and cortactin-cytoskeleton function leading to keratinocyte adhesion and differentiation," Journal of Biological Chemistry, vol. 279, no. 28, pp. 29654–29669, 2004.

[16] H. Ponta, L. Sherman, and P. A. Herrlich, "CD44: from adhesion molecules to signalling regulators," Nature Reviews Molecular Cell Biology, vol. 4, no. 1, pp. 33–49, 2003.

[17] C. Torre, S. J. Wang, W. Xia, and L. Y. W. Bourguignon, "Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling," Archives of Otolaryngology—Head & Neck Surgery, vol. 136, no. 5, pp. 493–501, 2010.

[18] M. S. Pandey, E. N. Harris, J. A. Weigel, and P. H. Weigel, "The cytoplasmic domain of the hyaluronan receptor for endocytosis (here) contains multiple endocytic motifs targeting coated pit-mediated internalization," The Journal of Biological Chemistry, vol. 283, no. 31, pp. 21453–21461, 2008.

[19] B. P. Toole, "Hyaluronan and its binding proteins, the hyaladherins," Current Opinion in Cell Biology, vol. 2, no. 5, pp. 839–844, 1990.

[20] L. Du, H. Wang, L. He et al., "CD44 is of functional importance for colorectal cancer stem cells," Clinical Cancer Research, vol. 14, no. 21, pp. 6751–6760, 2008.

[21] M. Kanke, M. Fujii, K. Kameyama et al., "Clinicopathological significance of expression of CD44 variants in head and neck squamous cell carcinoma," Japanese Journal of Cancer Research, vol. 91, no. 4, pp. 410–415, 2000.

[22] M. Kaufmann, G. von Minckwitz, K.-H. Heider, H. Ponta, P. Herrlich, and H.-P. Sinn, "CD44 variant exon epitopes in primary breast cancer and length of survival," The Lancet, vol. 345, no. 8950, pp. 615–619, 1995.

[23] C. Fillmore and C. Kuperwasser, "Human breast cancer stem cell markers CD44 and CD24: enriching for cells with functional properties in mice or in man?" Breast Cancer Research, vol. 9, article 303, 2007.

[24] R. Pirinen, P. Hirvonen, J. Böhm et al., "Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma," Human Pathology, vol. 31, no. 9, pp. 1088–1095, 2000.

[25] S. Kuhn, M. Koch, T. Nübel et al., "A complex of EpCAM, claudin-7, CD44 variant isoforms, and tetraspanins promotes colorectal cancer progression," Molecular Cancer Research, vol. 5, no. 6, pp. 553–567, 2007.

[26] S. Legras, U. Günther, R. Stauder et al., "A strong expression of CD44v6 correlates with shorter survival of patients with acute myeloid leukemia," Blood, vol. 91, no. 9, pp. 3401–3413, 1998.

[27] S. J. Wang and L. Y. W. Bourguignon, "Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance," American Journal of Pathology, vol. 178, no. 3, pp. 956–963, 2011.

[28] R. L. Brown, L. M. Reinke, M. S. Damerow et al., "CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression," Journal of Clinical Investigation, vol. 121, no. 3, pp. 1064–1074, 2011.

[29] A. M. Affy, S. Tate, B. Durbin-Johnson, D. M. Rocke, and T. Tábor, "Expression of CD44 and CD44v6 in lung cancer and their correlation with prognostic factors," International Journal of Biological Markers, vol. 26, no. 1, pp. 50–57, 2011.

[30] X.-D. Li, M. Ji, P. Jiang, X. Zhang, X. Li, and Z. Li, "CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma," Tumori, vol. 99, no. 1, pp. 88–92, 2013.

[31] Z. Li, K. Chen, P. Jiang, X. Zhang, X. Li, and Z. Li, "CD44v3/CD44v6 expression patterns are associated with the survival of pancreatic carcinoma patients," Diagnostic Pathology, vol. 9, article 79, 2014.

[32] B. Döme, B. Somlai, A. Ládányi, K. Fazekas, M. Zöller, and J. Timár, "Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma," Virchows Archiv, vol. 439, no. 5, pp. 628–635, 2001.
I. Fonseca, T. Pereira, J. Rosa-Santos, and J. Soares, "Expression of CD44 variant 9 is related to lymph node metastasis and poor survival in squamous cell carcinoma of the tongue," Oral Oncology, vol. 36, no. 6, pp. 545–549, 2000.

L. K. Diaz, X. Zhou, E. T. Wright et al., "CD44 expression is a marker of constitutive and reprogrammed cancer stem cells," Journal of Clinical Oncology, vol. 14, no. 4, pp. 1122–1127, 1996.

J. Ryś, A. Kru czak, B. Lackow ska et al., "The role of CD44v3 expression in female breast carcinomas," Polish Journal of Pathology, vol. 54, no. 4, pp. 243–247, 2003.

C. Sheridan, H. Kishimoto, R. K. Fuchs et al., "CD44v3/CD44v6 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis," Breast Cancer Research, vol. 8, article R59, 2006.

C. Templer, A. Losch, H. Heinzl et al., "Prognostic value of immunohistologically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer," European Journal of Cancer Part A, vol. 32, no. 11, pp. 2023–2025, 1996.

E. Olsson, G. Honeth, P.-O. Bendahl et al., "CD44 isoforms are heterogeneous in expressed in breast cancer and correlate with tumour subtypes and cancer stem cell markers," BMC Cancer, vol. 11, article 418, 2011.

L. J. Bendall and D. J. Gottlieb, "CD44 and adhesion of normal and leukemic CD44+ cells to bone marrow stroma," Leukemia & Lymphoma, vol. 32, no. 5–6, pp. 427–439, 1999.

E. Magyar osy, A. Sebesty en, and J. Timár, "Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia," Anticancer Research, vol. 21, no. 1, pp. 819–823, 2001.

L. J. Bendall, S. K. Nilsson, N. I. Khan et al., "Role of CD44 variant exon 6 in acute lymphoblastic leukaemia: association with altered bone marrow localisation and increased tumour burden," Leukemia, vol. 18, no. 7, pp. 1308–1311, 2004.

L. Jin, K. J. Hope, Q. Zhai, F. Smadja-Joffe, and J. E. Dick, "Targeting of CD44 eradicates human acute myeloid leukaemic stem cells," Nature Medicine, vol. 12, no. 10, pp. 1167–1174, 2006.

U. Erb, A. P. Megap tche, X. Gu, M. W. Büchler, and M. Zöller, "CD44 standard and CD44v10 isoform expression on leukaemia cells distinctly influences niche embedding of hematopoietic stem cells," Journal of Hematology and Oncology, vol. 7, article 29, 2014.

C. Fernandez-del Castillo and A. L. Warshaw, "Diagnosis and preoperative evaluation of pancreatic cancer, with implications for management," Gastroenterology Clinics of North America, vol. 19, no. 4, pp. 915–933, 1990.

F. Gansauge, S. Gansauge, A. Zobywalski et al., "Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in normal pancreas," Cancer Research, vol. 55, no. 23, pp. 5499–5503, 1995.

T. Gotoda, Y. Matsumura, H. Kondo et al., "Expression of CD44 variants and its association with survival in pancreatic cancer,"
S. Kiuchi, S. Ikeshita, Y. Miyatake, and M. Kasahara, "Pancreatic cancer cells express CD44 variant 9 and multidrug resistance protein 1 during mitosis," *Experimental and Molecular Pathology*, vol. 98, no. 1, pp. 41–46, 2015.

E. P. Reategui, A. A. de Mayolo, P. M. Das et al., "Characterization of CD44v3-containing isoforms in head and neck cancer," *Cancer Biology & Therapy*, vol. 5, no. 9, pp. 1163–1168, 2006.

T. Kawano, Y. Nakamura, S. Yanoma et al., "Expression of E-cadherin, and CD44v9 and CD44v6 and its association with prognosis in head and neck cancer," *Auris Nasus Larynx*, vol. 31, no. 1, pp. 35–41, 2004.

O. Nagano, S. Okazaki, and H. Saya, "Redox regulation in stem-like cancer cells by CD44 variant isoforms," *Oncogene*, vol. 32, no. 44, pp. 5191–5198, 2013.

T. Aso, M. Matsuo, H. Kiyohara et al., "Induction of CD44 variant 9-expressing cancer stem cells might attenuate the efficacy of chemoradiotherapy and worsens the prognosis of patients with advanced head and neck cancer," *PloS ONE*, vol. 10, no. 3, Article ID e011696, 2015.

K. Hirata, H. Suzuki, H. Imaeda et al., "CD44 variant 9 expression in primary early gastric cancer, vol. 109, no. 2, pp. 379–386, 2013.

M. Yoshikawa, K. Tsuchihashi, T. Ishimoto et al., "XCT inhibition depletes CD44v4-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma," *Cancer Research*, vol. 73, no. 6, pp. 1855–1866, 2013.

T. Ishimoto, O. Nagano, T. Yae et al., "CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth," *Cancer Cell*, vol. 19, no. 3, pp. 387–400, 2011.

T. Yae, K. Tsuchihashi, T. Ishimoto et al., "Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell," *Nature Communications*, vol. 3, article 883, 2012.

B. P. Toole, "Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities," *Clinical Cancer Research*, vol. 15, no. 24, pp. 7462–7468, 2009.

D. S. Krause, K. Lazarides, U. H. Von Andrian, and R. A. Van Etten, "Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells," *Nature Medicine*, vol. 12, no. 10, pp. 1175–1180, 2006.

I. Verel, K.-H. Heider, M. Siegmund et al., "Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44v6 in nude mice bearing head-and-neck cancer xenografts," *International Journal of Cancer*, vol. 99, no. 3, pp. 396–402, 2002.

D. R. Cohnot, J. C. Roos, R. de Bree et al., "Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIVA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck," *Cancer Immunology Immunotherapy*, vol. 52, no. 9, pp. 576–582, 2003.

P. K. E. Börjesson, E. J. Postema, J. C. Roos et al., "Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIVA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma," *Clinical Cancer Research*, vol. 9, no. 10, pp. 3961S–3972S, 2003.

B. M. Tijink, J. Buter, R. de Bree et al., "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus," *Clinical Cancer Research*, vol. 12, no. 20, pp. 6064–6072, 2006.

A. Sauter, C. Kloft, S. Gronau et al., "Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck," *International Journal of Oncology*, vol. 30, no. 4, pp. 927–933, 2007.

A. M. Alkilany, L. B. Thompson, S. P. Boulos, P. N. Sisco, and C. J. Murphy, "Gold nanorods: their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions," *Advanced Drug Delivery Reviews*, vol. 64, no. 2, pp. 190–199, 2012.

C. Zeng, B. P. Toole, S. D. Kinney, J.-W. Kuo, and I. Stamenkovic, "Inhibition of tumor growth in vivo by hyaluronan oligomers," *International Journal of Cancer*, vol. 77, no. 3, pp. 396–401, 1998.

N. Itano and K. Kimata, "Altered hyaluronan biosynthesis in cancer progression," *Seminars in Cancer Biology*, vol. 18, no. 4, pp. 268–274, 2008.

M. S. Karbownik and J. Z. Nowak, "Hyaluronan: towards novel anti-cancer therapeutics," *Pharmacological Reports*, vol. 65, no. 5, pp. 1056–1074, 2013.

J. Gaffney, S. Matou-Nasri, M. Grau-Olivares, and M. Slevin, "Therapeutic applications of hyaluronan," *Molecular BioSystems*, vol. 6, no. 3, pp. 437–443, 2010.

J. Liang, D. Jiang, and P. W. Noble, "Hyaluronan as a therapeutic target in human diseases," *Advanced Drug Delivery Reviews*, vol. 97, pp. 186–203, 2016.

N. Itano, T. Sawai, M. Yoshida et al., "Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties," *Journal of Biological Chemistry*, vol. 274, no. 35, pp. 25085–25092, 1999.

A. P. Spicer and J. Y. L. Tien, "Hyaluronan and Morphogenesis," *Birth Defects Research—Part C: Embryo Today: Reviews*, vol. 72, no. 1, pp. 89–108, 2004.

B. P. Toole, S. Ghattak, and S. Misra, "Hyaluronan oligosaccharides as a potential anticancer therapeutic," *Current Pharmaceutical Biotechnology*, vol. 9, no. 4, pp. 249–252, 2008.

J. Lesley, V. C. Hascall, M. Tammi, and R. Hyman, "Hyaluronan binding by cell surface CD44," *The Journal of Biological Chemistry*, vol. 275, no. 35, pp. 26967–26975, 2000.

C. B. Underhill and B. P. Toole, "Binding of hyaluronate to the surface of cultured cells," *Journal of Cell Biology*, vol. 82, no. 2, pp. 475–484, 1979.

M. G. Slomiany, L. Dai, P. A. Bomar et al., "Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides," *Cancer Research*, vol. 69, no. 12, pp. 4992–4998, 2009.

M. G. Slomiany, G. Daniel Grass, A. D. Robertson et al., "Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells," *Cancer Research*, vol. 69, no. 4, pp. 1293–1301, 2009.

A. G. Gilg, S. L. Tye, L. B. Tollervey et al., "Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors," *Clinical Cancer Research*, vol. 14, no. 6, pp. 1804–1813, 2008.

M. P. Ween, K. Hummitzsch, R. J. Rodgers, M. K. Oehler, and C. Ricciardelli, "Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan
oligosaccharides,” *Clinical and Experimental Metastasis*, vol. 28, no. 2, pp. 113–125, 2011.

[100] H. Urakawa, Y. Nishida, J. Wasa et al., “Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbellif erone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo,” *International Journal of Cancer*, vol. 130, no. 2, pp. 454–466, 2012.

[101] B. P. Tooze, “Hyaluronan: from extracellular glue to pericellular cue,” *Nature Reviews Cancer*, vol. 4, no. 7, pp. 528–539, 2004.

[102] K. Hosono, Y. Nishida, W. Knudson et al., “Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells,” *The American Journal of Pathology*, vol. 171, no. 1, pp. 274–286, 2007.

[103] R. Stern, “Hyaluronidases in cancer biology,” *Seminars in Cancer Biology*, vol. 18, no. 4, pp. 275–280, 2008.

[104] H. Bouga, I. Tsouros, D. Bounias et al., “Involvement of hyaluronidases in colorectal cancer,” *BMC Cancer*, vol. 10, article 499, 2010.

[105] J.-X. Tan, X.-Y. Wang, X.-L. Su et al., “Upregulation of HYALI expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis,” *PloS ONE*, vol. 6, no. 7, Article ID e22836, 2011.

[106] V. B. Lokeshwar, W. H. Cerwinka, T. Isoyama, and B. L. Lokeshwar, “HYALI hyaluronidase in prostate cancer: a tumor promoter and suppressor,” *Cancer Research*, vol. 65, no. 17, pp. 7782–7789, 2005.

[107] M. A. Simpson and V. B. Lokeshwar, “Hyaluronan and hyaluronidase in genitourinary tumors,” *Frontiers in Bioscience*, vol. 13, pp. 5664–5680, 2008.

[108] E. J. Franzmann, G. L. Schroeder, W. J. Goodwin, D. T. Weed, P. Fisher, and V. B. Lokeshwar, “Expression of tumor markers hyaluronic acid and hyaluronidase (HYALI) in head and neck tumors,” *International Journal of Cancer*, vol. 106, no. 3, pp. 438–445, 2003.

[109] B. Delpech, A. Laquerriere, C. Maingonnat, P. Bertrand, and P. Freger, “Hyaluronidase is more elevated in human brain metastases than in primary brain tumours,” *Anticancer Research*, vol. 22, no. 4, pp. 2423–2427, 2002.

[110] S. Eissa, H. Shehata, A. Mansour, M. Esmat, and O. El-Ahmady, “Detection of hyaluronidase RNA and activity in urine of schistosomal and non-schistosomal bladder cancer,” *Medical Oncology*, vol. 29, no. 5, pp. 3345–3351, 2012.

[111] Y. K. de Sá, E. Olivieri, E. R. Parra et al., “Hyaluronidase splice variants are associated with histology and outcome in adenocarcinoma and squamous cell carcinoma of the lung,” *Human Pathology*, vol. 43, no. 5, pp. 675–683, 2012.

[112] G. Baumgartner, C. Gomar-Höss, L. Sakr, E. Ulsgaer, and C. Wogritz, “The impact of extracellular matrix on the chemoresistance of solid tumors—experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy,” *Cancer Letters*, vol. 131, no. 1, pp. 85–99, 1998.

[113] S. Shuster, G. I. Frost, L. M. Ziebell, and G. D. Prestwich, “A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells,” *International Journal of Cancer*, vol. 48, no. 19, pp. 3280–3294, 2010.

[114] D. L. J. Thorek, A. K. Chen, J. Czupryna, and A. Tsourkas, “Superparamagnetic iron oxide nanoparticle probes for molecular imaging,” *Annals of Biomedical Engineering*, vol. 34, no. 1, pp. 23–38, 2006.

[115] X. Michalet, F. F. Pinaud, L. A. Bentolila et al., “Quantum dots for live cells, in vivo imaging, and diagnostics,” *Science*, vol. 307, no. 5709, pp. 538–544, 2005.

[116] J. Cichy and E. Puré, “The liberation of CD44,” *Journal of Cell Biology*, vol. 161, no. 5, pp. 839–843, 2003.

[117] K. Y. Choi, K. H. Min, H. Y. Yoon et al., “PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo,” *Biomaterials*, vol. 32, no. 7, pp. 1880–1889, 2011.

[118] I. Rivkin, K. Cohen, J. Koffler, D. Melikhov, D. Peer, and R. Margalit, “Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors,” *Biomaterials*, vol. 31, no. 27, pp. 7106–7114, 2010.

[119] G. Bacher, K. Cohen, R. Hod et al., “Hyaluronan-grafted particle clusters loaded with Mitomycin C as selective nanovectors for primary head and neck cancers,” *Biomaterials*, vol. 32, no. 21, pp. 4840–4848, 2011.

[120] D. A. Gewirtz, M. L. Bristol, and J. C. Yalowich, “Toxicity issues in cancer drug development,” *Current Opinion in Investigational Drugs*, vol. 11, no. 6, pp. 612–614, 2010.

[121] R. Pérez-Tomás, “Multidrug resistance: retrospect and prospects in anti-cancer drug treatment,” *Current Medicinal Chemistry*, vol. 13, no. 16, pp. 1859–1876, 2006.

[122] M. M. Gottesman, T. Fojo, and S. E. Bates, “Multidrug resistance in cancer: role of ATP-dependent transporters,” *Nature Reviews Cancer*, vol. 2, no. 1, pp. 48–58, 2002.

[123] M. M. Gottesman and V. Ling, “The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research,” *FEBS Letters*, vol. 580, no. 4, pp. 998–1009, 2006.

[124] K. Akima, H. Ito, Y. Iwata et al., “Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity,” *Journal of Drug Targeting*, vol. 4, no. 1, pp. 1–8, 1996.

[125] R. E. Eliazi and F. C. Szoka, “Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells,” *Cancer Research*, vol. 61, no. 6, pp. 2592–2601, 2001.

[126] Y. Luo, M. R. Ziebell, and G. D. Prestwich, “A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells,” *Biomacromolecules*, vol. 1, no. 2, pp. 208–218, 2000.

[127] D. Frank, C. Tyagi, L. Tomar et al., “Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors,” *International Journal of Nanomedicine*, vol. 9, no. 1, pp. 589–613, 2014.

[128] M. Kamat, K. El-Boubbou, D. C. Zhu et al., “Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages,” *Bioconjugate Chemistry*, vol. 21, no. 11, pp. 2128–2135, 2010.

[129] D. A. Giljohann, D. S. Seferos, W. L. Daniel, M. D. Massich, P. C. Patel, and C. A. Mirkin, “Gold nanoparticles for biology and medicine,” *Angewandte Chemie—International Edition*, vol. 49, no. 19, pp. 3280–3294, 2010.

[130] D. L. J. Thorek, A. K. Chen, J. Czupryna, and A. Tsourkas, “Superparamagnetic iron oxide nanoparticle probes for molecular imaging,” *Annals of Biomedical Engineering*, vol. 34, no. 1, pp. 23–38, 2006.

[131] X. Michalet, F. F. Pinaud, L. A. Bentolila et al., “Quantum dots for live cells, in vivo imaging, and diagnostics,” *Science*, vol. 307, no. 5709, pp. 538–544, 2005.

[132] J. L. Gilmore, X. Yi, L. Quan, and A. V. Kabanov, “Novel nanoparticles for clinical neuroscience,” *Journal of Neuroummune Pharmacology*, vol. 3, no. 2, pp. 83–94, 2008.

[133] T. J. Deerinck, “The application of fluorescent quantum dots to confocal, multiphoton, and electron microscopic imaging,” *Toxicologic Pathology*, vol. 36, no. 1, pp. 112–116, 2008.
[134] S. J. Son, X. Bai, and S. B. Lee, “Inorganic hollow nanoparticles and nanotubes in nanomedicine. Part 1. Drug/gene delivery applications,” Drug Discovery Today, vol. 12, no. 15-16, pp. 650–656, 2007.

[135] R. Thapa and G. D. Wilson, “Head and neck cancer: current treatment options and associated challenges,” Scholars Journal of Applied Medical Sciences, vol. 4, no. 2, pp. 590–600, 2016.

[136] H. Lee, H. Mok, S. Lee, Y.-K. Oh, and T. G. Park, “Target-specific intracellular delivery of siRNA using degradable hyaluronic acid nanogels,” Journal of Controlled Release, vol. 119, no. 2, pp. 245–252, 2007.

[137] S. Misra, V. C. Hascll, R. R. Markwald, and S. Ghatak, “Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer,” Frontiers in Immunology, vol. 6, article 201, 2015.

[138] T. Pellegrino, S. Kudera, T. Liedl, A. M. Javier, L. Manna, and W. J. Parak, “On the development of colloidal nanoparticles towards multifunctional structures and their possible use for biological applications,” Small, vol. 1, no. 1, pp. 48–63, 2005.

[139] R. Tenne, “Inorganic nanotubes and fullerene-like nanoparticles,” Nature Nanotechnology, vol. 1, no. 2, pp. 103–116, 2006.

[140] L. Bao, Z.-L. Zhang, Z.-Q. Tian et al., “Electrochemical tuning of luminescent carbon nanodots: from preparation to luminescence mechanism,” Advanced Materials, vol. 23, no. 48, pp. 5801–5806, 2011.

[141] A. K. Geim, “Graphene: status and prospects,” Science, vol. 324, no. 5934, pp. 1530–1534, 2009.

[142] M.-Y. Lee, J.-A. Yang, H. S. Jung et al., “Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection,” ACS Nano, vol. 6, no. 11, pp. 9522–9531, 2012.

[143] A. Kumar, B. Sahoo, A. Montpetit, S. Behera, R. E. Lockey, and S. S. Mohapatra, “Development of hyaluronic acid-Fe3O4 hybrid magnetic nanoparticles for targeted delivery of peptides,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 3, no. 2, pp. 132–137, 2007.

[144] H.-J. Cho, H. Y. Yoon, H. Koo et al., “Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel,” Biomaterials, vol. 32, no. 29, pp. 7181–7190, 2011.

[145] H. X. Shen, S. J. Shi, Z. R. Zhang, T. Gong, and X. Sun, “Coating solid lipid nanoparticles with hyaluronic acid enhances anti-tumor activity against melanoma stem-like cells,” Theranostics, vol. 5, no. 7, pp. 755–771, 2015.

[146] M. H. El-Dakkouhi, K. El-Boubbou, M. Kamat et al., “CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging,” Pharmaceutical Research, vol. 31, no. 6, pp. 1426–1437, 2014.

[147] M. H. El-Dakkouhi, K. El-Boubbou, D. C. Zhu, and X. Huang, “A simple method for the synthesis of hyaluronic acid coated magnetic nanoparticles for highly efficient cell labelling and in vivo imaging,” RSC Advances, vol. 1, no. 8, pp. 1449–1452, 2011.

[148] K. El-Boubbou, D. C. Zhu, C. Vasileiou et al., “Magnetic glyconanoparticles: a tool to detect, differentiate, and unlock the glyco-codes of cancer via magnetic resonance imaging,” Journal of the American Chemical Society, vol. 132, no. 12, pp. 4490–4499, 2010.

[149] A. K. Gupta and A. S. G. Curtis, “Lactoferrin and ceruloplasmin derivatized superparamagnetic iron oxide nanoparticles for targeting cell surface receptors,” Biomaterials, vol. 25, no. 15, pp. 3029–3040, 2004.

[150] M. Babic, D. Horák, M. Trchová et al., “Poly(L-lysine)-modified iron oxide nanoparticles for stem cell labeling,” Bioconjugate Chemistry, vol. 19, no. 3, pp. 740–750, 2008.

[151] D. Horák, B. Rittich, A. Španová, and M. J. Beneš, “Magnetic microparticulate carriers with immobilized selective ligands in DNA diagnostics,” Polymer, vol. 46, no. 4, pp. 1245–1255, 2005.

[152] A. K. Gupta and M. Gupta, “Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications,” Biomaterials, vol. 26, no. 18, pp. 3995–4021, 2005.

[153] A. Jordan, R. Scholz, K. Maier-Hauff et al., “Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermia,” Journal of Magnetism and Magnetic Materials, vol. 225, no. 1-2, pp. 118–126, 2001.

[154] T. Neuberger, B. Schön, H. Hofmann, M. Hofmann, and B. Von Rechenberg, “Superparamagnetic nanoparticles for biomedical applications: possibilities and limitations of a new drug delivery system,” Journal of Magnetism and Magnetic Materials, vol. 293, no. 1, pp. 483–496, 2005.

[155] R. Thapa, S. Galofo, S. M. Kandel et al., “Radiosensitizing and hyperthermic properties of hyaluronan conjugated, dextran-coated ferric oxide nanoparticles: implications for cancer stem cell therapy,” Journal of Nanomaterials, vol. 2015, Article ID 840594, II pages, 2015.

[156] Q. Zhao, L. N. Wang, R. Cheng et al., “Magnetic nanoparticle-based hyperthermia for head & neck cancer in mouse models,” Theranostics, vol. 2, no. 1, pp. 113–121, 2012.

[157] K. K. Ang, N. H. Andratschke, and L. Milas, “Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 3, pp. 959–965, 2004.

[158] G. Wyse, H. Hong, and K. Murphy, “Percutaneous thermal ablation in the head and neck: current role and future applications,” Neuroimaging Clinics of North America, vol. 19, no. 2, pp. 161–168, 2009.

[159] H. S. Huang and J. F. Hainfeld, “Intravenous magnetic nanoparticle cancer hyperthermia,” International Journal of Nanomedicine, vol. 8, pp. 2521–2532, 2013.

[160] R. G. Thomas, M. J. Moon, H. Lee et al., “Hyaluronic acid conjugated superparamagnetic iron oxide nanoparticle for cancer diagnosis and hyperthermia therapy,” Carbohydrate Polymers, vol. 131, pp. 439–446, 2015.

[161] J. M. V. Louderbough and J. A. Schroeder, “Understanding the dual nature of CD44 in breast cancer progression,” Molecular Cancer Research, vol. 9, no. 12, pp. 1573–1586, 2011.

[162] T. A. Martin, G. Harrison, R. E. Mansel, and W. G. Jiang, “The role of the CD44/ezrin complex in cancer metastasis,” Critical Reviews in Oncology/Hematology, vol. 46, no. 2, pp. 165–186, 2003.

[163] V. J. M. Wielenga, R. van der Neut, G. J. A. Offerhaus, and S. T. Pals, “CD44 glycoproteins in colorectal cancer: expression, function, and prognostic value,” Advances in Cancer Research, vol. 77, pp. 169–187, 2000.

[164] E. M. Castellà, A. Ariza, I. Pellicer, A. Fernández-Vasalo, and I. Ojanguren, “Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma,” Journal of Clinical Pathology, vol. 51, no. 2, pp. 134–137, 1998.

[165] T. A. Tran, B. V. S. Kallakury, C. E. Sheehan, and J. S. Ross, “Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas,” Human Pathology, vol. 28, no. 7, pp. 809–814, 1997.
[166] R. Stauder, M. Van Driel, C. Schwärzler et al., “Different CD44 splicing patterns define prognostic subgroups in multiple myeloma,” Blood, vol. 88, no. 8, pp. 3101–3108, 1996.

[167] C. Beham-Schmid, K. H. Heider, G. Hoefler, and K. Zatloukal, “Expression of CD44 splice variant v10 in Hodgkin’s disease is associated with aggressive behaviour and high risk of relapse,” The Journal of Pathology, vol. 186, no. 4, pp. 383–389, 1998.

[168] R. Stauder, W. Eisterer, J. Thaler, and U. Gunther, “CD44 variant isoforms in non-Hodgkin’s lymphoma: a new independent prognostic factor,” Blood, vol. 85, no. 10, pp. 2885–2899, 1995.

[169] R. Ristamaki, H. Joensuu, K.-O. Soderstrom, and S. Jalkanen, “CD44v6 expression in non-Hodgkin’s lymphoma: an association with low histological grade and poor prognosis,” The Journal of Pathology, vol. 176, no. 3, pp. 259–267, 1995.

[170] T. Gotoda, T. Kakizoe, Y. Matsumura et al., “Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma,” Gut, vol. 46, no. 1, pp. 14–19, 2000.

[171] J. P. Böhm, L. K. Niskanen, R. T. Pirinen et al., “Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma,” Journal of Pathology, vol. 192, no. 3, pp. 321–327, 2000.

[172] K. A. Iczkowski, J. H. Shanks, and D. G. Bostwick, “Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma,” Histopathology, vol. 32, no. 4, pp. 322–327, 1998.

[173] P. Lipponen, S. Aaltoma, V.-M. Kosma, M. Ala-Opas, and M. Eskelinen, “Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up,” Journal of Pathology, vol. 186, no. 2, pp. 157–164, 1998.

[174] P. Dall, A. Hekele, H. Ikenberg et al., “Increasing incidence of CD44v7/8 epitope expression during uterine cervical carcinogenesis,” International Journal of Cancer, vol. 69, no. 2, pp. 79–85, 1996.

[175] A. Ayhan, C. Baykal, A. Al, and A. Ayhan, “Altered CD44 variant 6 expression in FIGO stage IB cervical carcinoma,” Gynecologic Oncology, vol. 83, no. 3, pp. 569–574, 2001.